GenVec Inc(NASDAQ:GNVC) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 5, 2016. Company reported revenue of $26.00K. Analysts estimated a revenue of $100.00K. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.10.
In a different note, On Jun 20, 2016, Rodman & Renshaw said it Assumes its rating on GenVec Inc. The shares have been rated ‘Buy’ by the firm.
GenVec Inc (GNVC) made into the market gainers list on Wednesdays trading session with the shares advancing 1.63% or 0.0101 points. Due to strong positive momentum, the stock ended at $0.6301, which is also near the day’s high of $0.65. The stock began the session at $0.62 and the volume stood at 1,21,780 shares. The 52-week high of the shares is $3.69 and the 52 week low is $0.35. The company has a current market capitalization of $14 M and it has 2,27,36,316 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Dec 15, 2015, Douglas J Swirsky (CEO) purchased 5,000 shares at $2.00 per share price.Also, On Nov 18, 2015, Stefan Loren (director) purchased 4,000 shares at $1.93 per share price.On Aug 11, 2015, Douglas E Brough (Chief Scientific Officer) purchased 4,600 shares at $2.34 per share price, according to the Form-4 filing with the securities and exchange commission.
GenVec Inc. (GenVec) is a clinical-stage biopharmaceutical company engaged in the development of therapeutics and vaccines. The Company designs tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas such as hearing loss and balance disorders as well as vaccines against infectious diseases including respiratory syncytial virus (RSV) herpes simplex virus (HSV) Enterovirus D68 (EV-D68) and malaria. The Company develops and commercializes its product candidates through collaborations. In collaboration with Novartis the Company’s hearing and balance disorders program is involved in the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. In the area of animal health the Company with its collaborators is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.